Background Patients with disorders of consciousness(DoC)exhibit varied revival outcomes based on different etiologies and diagnoses,the mechanisms of which remain largely unknown.The fluctuating clinical presentations...Background Patients with disorders of consciousness(DoC)exhibit varied revival outcomes based on different etiologies and diagnoses,the mechanisms of which remain largely unknown.The fluctuating clinical presentations in DoC pose challenges in accurately assessing consciousness levels and prognoses,often leading to misdiagnoses.There is an urgent need for a deeper understanding of the physiological changes in DoC and the development of objective diagnostic and prognostic biomarkers to improve treatment guidance.Methods To explore biomarkers and understand the biological processes,we conducted a comprehensive untargeted metabolomic analysis on serum samples from 48 patients with DoC.Patients were categorized based on etiology(TBI vs.non-TBI),CRS-R scores,and prognosis.Advanced analytical techniques,including PCA and OPLS-DA models,were employed to identify differential metabolites.Results Our analysis revealed a distinct separation in metabolomic profiles among the different groups.The primary differential metabolites distinguishing patients with varying etiologies were predominantly phospholipids,with a notable decrease in glycerophospholipids observed in the TBI group.Patients with higher CRS-R scores exhibited a pattern of impaired carbohydrate metabolism coupled with enhanced lipid metabolism.Notably,serum concentrations of both LysoPE and PE were reduced in patients with improved outcomes,suggesting their potential as prognostic biomarkers.Conclusions Our study underscores the critical role of phospholipid metabolism in the brain’s metabolic alterations in patients with DoC.It identifies key biomarkers for diagnosis and prognosis,offering insights that could lead to novel therapeutic targets.These findings highlight the value of metabolomic profiling in understanding and potentially treating DoC.展开更多
To the Editor:Amyloidosis is caused by the extracellular deposition of insoluble beta-pleated protein fibrils in tissues and is classified according to the constituent proteins.The cause of amyloidosis can be traced t...To the Editor:Amyloidosis is caused by the extracellular deposition of insoluble beta-pleated protein fibrils in tissues and is classified according to the constituent proteins.The cause of amyloidosis can be traced to more than 30 kinds of malfolded proteins,and accurate amyloid typing is crucial for appropriate therapy.[1]The pathological diagnosis is confirmed with positive Congo red(CR)staining under a light microscope and 7 to 12 nm branching fibrils under an electron microscope.Further identification of some amyloid precursor proteins can resort to immunofluorescence(IF)and immunochemistry(IHC);however,the accuracy depends on the selected antibodies to a large extent.Laser microdissection coupled with liquid chromatography-tandem mass spectrometry(LMD/MS)can identify these proteins without the restriction of IF and IHC,although exquisite equipment and skilled specialists are required.[2]This study aimed to establish LMD/MS analysis of renal biopsy tissue and compare it with IHC on diagnostic sensitivity.展开更多
基金supported by the National Key Research and Development Program of China(No.2021ZD0204200)National Natural Science Foundation of China(No.82170524,31901039)+2 种基金Beijing Medical Research(No.2018-7)CAMS Innovation Fund for Medical Sciences(2021-I2M-1-016)Biologic Medicine Information Center of China,National Scientific Data Sharing Platform for Population and Health.
文摘Background Patients with disorders of consciousness(DoC)exhibit varied revival outcomes based on different etiologies and diagnoses,the mechanisms of which remain largely unknown.The fluctuating clinical presentations in DoC pose challenges in accurately assessing consciousness levels and prognoses,often leading to misdiagnoses.There is an urgent need for a deeper understanding of the physiological changes in DoC and the development of objective diagnostic and prognostic biomarkers to improve treatment guidance.Methods To explore biomarkers and understand the biological processes,we conducted a comprehensive untargeted metabolomic analysis on serum samples from 48 patients with DoC.Patients were categorized based on etiology(TBI vs.non-TBI),CRS-R scores,and prognosis.Advanced analytical techniques,including PCA and OPLS-DA models,were employed to identify differential metabolites.Results Our analysis revealed a distinct separation in metabolomic profiles among the different groups.The primary differential metabolites distinguishing patients with varying etiologies were predominantly phospholipids,with a notable decrease in glycerophospholipids observed in the TBI group.Patients with higher CRS-R scores exhibited a pattern of impaired carbohydrate metabolism coupled with enhanced lipid metabolism.Notably,serum concentrations of both LysoPE and PE were reduced in patients with improved outcomes,suggesting their potential as prognostic biomarkers.Conclusions Our study underscores the critical role of phospholipid metabolism in the brain’s metabolic alterations in patients with DoC.It identifies key biomarkers for diagnosis and prognosis,offering insights that could lead to novel therapeutic targets.These findings highlight the value of metabolomic profiling in understanding and potentially treating DoC.
基金the National Key Research and Development Program of China(No.2016YFC0901500).
文摘To the Editor:Amyloidosis is caused by the extracellular deposition of insoluble beta-pleated protein fibrils in tissues and is classified according to the constituent proteins.The cause of amyloidosis can be traced to more than 30 kinds of malfolded proteins,and accurate amyloid typing is crucial for appropriate therapy.[1]The pathological diagnosis is confirmed with positive Congo red(CR)staining under a light microscope and 7 to 12 nm branching fibrils under an electron microscope.Further identification of some amyloid precursor proteins can resort to immunofluorescence(IF)and immunochemistry(IHC);however,the accuracy depends on the selected antibodies to a large extent.Laser microdissection coupled with liquid chromatography-tandem mass spectrometry(LMD/MS)can identify these proteins without the restriction of IF and IHC,although exquisite equipment and skilled specialists are required.[2]This study aimed to establish LMD/MS analysis of renal biopsy tissue and compare it with IHC on diagnostic sensitivity.
